{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:59:01Z","timestamp":1790222341200,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejpn.2024.02.010","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T23:20:00Z","timestamp":1709248800000},"page":"95-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Vaccination proposal for patients on onasemnogene abeparvovec therapy"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7768-7803","authenticated-orcid":false,"given":"Sarolta","family":"Dobner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kulcs\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Liptai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Vojnisek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9291-295X","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-1378","authenticated-orcid":false,"given":"L\u00e9na","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejpn.2024.02.010_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy\u2013a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"10.1016\/j.ejpn.2024.02.010_bib2","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/brain\/awf155","article-title":"Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord","volume":"125","author":"Soler-Botija","year":"2002","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.ejpn.2024.02.010_bib3","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","article-title":"Time is motor neuron: therapeutic Window and its correlation with pathogenetic mechanisms in spinal muscular atrophy","volume":"55","author":"Govoni","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.ejpn.2024.02.010_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejpn.2024.02.010_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/jpc.16340","article-title":"Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: a systematic review and meta-analysis","volume":"59","author":"Yang","year":"2023","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.ejpn.2024.02.010_bib6","unstructured":"SUMMARY of PRODUCT CHARACTERISTICS Zolgensma."},{"key":"10.1016\/j.ejpn.2024.02.010_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.thromres.2023.02.012","article-title":"Eculizumab in the management of drug-induced thrombotic microangiopathy: a scoping review of the literature","volume":"224","author":"Zafar","year":"2023","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejpn.2024.02.010_bib8","article-title":"Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpn.2024.02.010_bib9","first-page":"888","article-title":"Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy","volume":"164","author":"Starck","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.ejpn.2024.02.010_bib10","first-page":"478","article-title":"Secondary thrombotic microangiopathy and eculizumab: a reasonable therapeutic option","volume":"37","author":"Roman","year":"2017","journal-title":"Nefrologia"},{"key":"10.1016\/j.ejpn.2024.02.010_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.sleep.2023.09.019","article-title":"Sleep disordered breathing in infants identified through newborn screening with spinal muscular atrophy","volume":"111","author":"Chiang","year":"2023","journal-title":"Sleep Med."},{"issue":"25","key":"10.1016\/j.ejpn.2024.02.010_bib12","first-page":"971","article-title":"Reducing the risk of infections in hereditary and acquired complement deficiencies","volume":"164","author":"\u00c9","year":"2023","journal-title":"Orv. Hetil."},{"key":"10.1016\/j.ejpn.2024.02.010_bib14","author":"site ATAGoI-e"},{"key":"10.1016\/j.ejpn.2024.02.010_bib15","unstructured":"Glucocorticoid effects on the immune system [Internet] 11\/OCT\/2023]. Available from: Wolters Kluwer (2023). https:\/\/www.uptodate.com\/contents\/glucocorticoid-effects-on-the-immune-system. online source, no volume and page available."},{"issue":"1","key":"10.1016\/j.ejpn.2024.02.010_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"Weiss","year":"2022","journal-title":"Lan. Child Adolesc Health"},{"key":"10.1016\/j.ejpn.2024.02.010_bib17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00115-020-00919-8","volume":"91","author":"Ziegler","year":"2020","journal-title":"Nervenarzt"},{"issue":"14","key":"10.1016\/j.ejpn.2024.02.010_bib18","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejpn.2024.02.010_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr. Nephrol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.02.010_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12882-021-02470-3","article-title":"Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre","volume":"22","author":"Grall","year":"2021","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ejpn.2024.02.010_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ejpn.2024.02.010_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ejpn.2024.02.010_bib23","series-title":"High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine","first-page":"2481","author":"McNamara","year":"2017"},{"issue":"1","key":"10.1016\/j.ejpn.2024.02.010_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MPG.0000000000003268","article-title":"North American society for pediatric gastroenterology, hepatology, and nutrition position paper on the diagnosis and management of pediatric acute liver failure","volume":"74","author":"Squires","year":"2022","journal-title":"J.\u00a0Pediatr. Gastroenterol. Nutr."},{"issue":"3","key":"10.1016\/j.ejpn.2024.02.010_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001012","article-title":"The BCG World Atlas: a database of global BCG vaccination policies and practices","volume":"8","author":"Zwerling","year":"2011","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejpn.2024.02.010_bib26","series-title":"The BCG World Atlas","author":"Pai","year":"2020"},{"issue":"6","key":"10.1016\/j.ejpn.2024.02.010_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jinf.2012.03.012","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) complications associated with primary immunodeficiency diseases","volume":"64","author":"Norouzi","year":"2012","journal-title":"J.\u00a0Infect."},{"issue":"4","key":"10.1016\/j.ejpn.2024.02.010_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094485","article-title":"Clinical characteristics and immunogenetics of BCGosis\/BCGitis in Chinese children: a 6 year follow-up study","volume":"9","author":"Ying","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpn.2024.02.010_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s10875-019-00642-3","article-title":"Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity","volume":"39","author":"P\u00f6yh\u00f6nen","year":"2019","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.ejpn.2024.02.010_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10875-020-00892-6","article-title":"Bacillus Calmette\u2013Guerin (BCG) vaccine-associated complications in immunodeficient patients following stem cell transplantation","volume":"41","author":"NaserEddin","year":"2021","journal-title":"J.\u00a0Clin. Immunol."},{"issue":"18_suppl","key":"10.1016\/j.ejpn.2024.02.010_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.14507","article-title":"Safety and efficacy of intravesical bacillus Calmette-Gu\u00e9rin instillations in steroid-treated and immunocompromised patients","volume":"24","author":"Yossepowitch","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejpn.2024.02.010_bib32","series-title":"Timing and Spacing of Immunobiologics, General Best Practice Guidelines for Immunization","author":"Diseases NCfIaR","year":"2023"},{"key":"10.1016\/j.ejpn.2024.02.010_bib33","series-title":"Child and Adolescent Immunization Schedule by Age, Recommendations for Ages 18 Years or Younger, United States, 2023","author":"Diseases NCfIaR","year":"2023"},{"issue":"4","key":"10.1016\/j.ejpn.2024.02.010_bib36","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.inf.0000059446.52063.b9","article-title":"Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose","volume":"22","author":"Fiore","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"6","key":"10.1016\/j.ejpn.2024.02.010_bib37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0264-410X(98)00237-0","article-title":"Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme","volume":"17","author":"Piazza","year":"1999","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ejpn.2024.02.010_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/01.inf.0000253253.85640.cc","article-title":"Immunogenicity of an inactivated hepatitis A vaccine in infants and young children","volume":"26","author":"Bell","year":"2007","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.ejpn.2024.02.010_bib39","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jcpa.2007.04.011","article-title":"Vaccination of newborns against hepatitis A in the presence of maternally derived antibodies","volume":"137","author":"Vidor","year":"2007","journal-title":"J.\u00a0Comp. Pathol."},{"issue":"3","key":"10.1016\/j.ejpn.2024.02.010_bib40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpeds.2003.11.030","article-title":"Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants","volume":"144","author":"Letson","year":"2004","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ejpn.2024.02.010_bib41","series-title":"Brown GAaK. Guidelines on Post Exposure Prophylaxis (PEP) for Varicella or Shingles","year":"2023"},{"key":"10.1016\/j.ejpn.2024.02.010_bib42","series-title":"Tetanus: Centers for Disease Control and Prevention","year":"2022"},{"issue":"3","key":"10.1016\/j.ejpn.2024.02.010_bib43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm6903a5","article-title":"Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States","volume":"69","author":"Havers","year":"2020","journal-title":"MMWR (Morb. Mortal. Wkly. Rep.)"},{"issue":"52","key":"10.1016\/j.ejpn.2024.02.010_bib44","doi-asserted-by":"crossref","first-page":"7916","DOI":"10.1016\/j.vaccine.2018.10.070","article-title":"Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany","volume":"36","author":"Matysiak-Klose","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.ejpn.2024.02.010_bib45","article-title":"Prevention of hepatitis A through active or passive immunization: recommendations of the advisory committee on immunization practices (ACIP)","volume":"55","author":"Fiore","year":"2006","journal-title":"MMWR Recomm. Rep. (Morb. Mortal. Wkly. Rep.)"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:42:18Z","timestamp":1761072138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379824000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":42,"alternative-id":["S1090379824000175"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.02.010","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination proposal for patients on onasemnogene abeparvovec therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}